

Harikrishna Nakshatri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1857165/harikrishna-nakshatri-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182
papers

13,266
citations

60
h-index

113
g-index

195
ext. papers

14,340
ext. citations

7.6
avg, IF

6.12
L-index

#	Paper	IF	Citations
182	Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity.. <i>Science Advances</i> , 2022 , 8, eabh3375	14.3	3
181	Aberrant epigenetic and transcriptional events associated with breast cancer risk.. <i>Clinical Epigenetics</i> , 2022 , 14, 21	7.7	1
180	Acquisition, processing, and single-cell analysis of normal human breast tissues from a biobank.. <i>STAR Protocols</i> , 2022 , 3, 101047	1.4	0
179	FAM83A is a potential biomarker for breast cancer initiation.. <i>Biomarker Research</i> , 2022 , 10, 8	8	0
178	Abstract P3-14-13: Metabolic links to socioeconomic stresses uniquely affecting race in normal breast tissue at risk for breast cancer. <i>Cancer Research</i> , 2022 , 82, P3-14-13-P3-14-13	10.1	
177	Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations.. <i>Molecular Therapy - Nucleic Acids</i> , 2022 , 28, 231-248	10.7	0
176	Aged Breast Extracellular Matrix Drives Mammary Epithelial Cells to an Invasive and Cancer-Like Phenotype. <i>Advanced Science</i> , 2021 , 8, e2100128	13.6	3
175	Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma. <i>Molecular Cancer Research</i> , 2021 , 19, 1168-1181	6.6	3
174	A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells. <i>Cell Reports Medicine</i> , 2021 , 2, 100219	18	3
173	Mechanical tibial loading remotely suppresses brain tumors by dopamine-mediated downregulation of CCN4. <i>Bone Research</i> , 2021 , 9, 26	13.3	2
172	Aging-associated skeletal muscle defects in HER2/Neu transgenic mammary tumor model. <i>JCSM Rapid Communications</i> , 2021 , 4, 24-39	2.6	3
171	Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression. <i>Oncogene</i> , 2021 , 40, 1332-1346	9.2	1
170	Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	13
169	A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment. <i>PLoS ONE</i> , 2021 , 16, e0225869	3.7	1
168	Overexpression of Lrp5 enhanced the anti-breast cancer effects of osteocytes in bone. <i>Bone Research</i> , 2021 , 9, 32	13.3	7
167	Bidirectional Regulatory Cross-Talk between Cell Context and Genomic Aberrations Shapes Breast Tumorigenesis. <i>Molecular Cancer Research</i> , 2021 , 19, 1802-1817	6.6	2
166	Hormonally Regulated Myogenic miR-486 Influences Sex-specific Differences in Cancer-induced Skeletal Muscle Defects. <i>Endocrinology</i> , 2021 , 162,	4.8	1

165	Building a virtual summer research experience in cancer for high school and early undergraduate students: lessons from the COVID-19 pandemic. <i>BMC Medical Education</i> , 2021 , 21, 422	3.3	2
164	Antitumor properties of novel sesquiterpene lactone analogs as NFB inhibitors that bind to the IKK γ ubiquitin-like domain (ULD). <i>European Journal of Medicinal Chemistry</i> , 2021 , 224, 113675	6.8	2
163	In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. <i>PLoS Genetics</i> , 2020 , 16, e1008808	6	15
162	Skeletal loading regulates breast cancer-associated osteolysis in a loading intensity-dependent fashion. <i>Bone Research</i> , 2020 , 8, 9	13.3	24
161	Systemic Actions of Breast Cancer Facilitate Functional Limitations. <i>Cancers</i> , 2020 , 12,	6.6	6
160	regSNPs-ASB: A Computational Framework for Identifying Allele-Specific Transcription Factor Binding From ATAC-seq Data. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020 , 8, 886	5.8	2
159	Breast Cancer Cell Detection and Characterization from Breast Milk-Derived Cells. <i>Cancer Research</i> , 2020 , 80, 4828-4839	10.1	3
158	Cell competition and tumor heterogeneity. <i>Seminars in Cancer Biology</i> , 2020 , 63, 1-10	12.7	15
157	Breast Heterogeneity: Obstacles to Developing Universal Biomarkers of Breast Cancer Initiation and Progression. <i>Journal of the American College of Surgeons</i> , 2020 , 231, 85-96	4.4	2
156	Dual TGF β /BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast. <i>Molecular Cancer Research</i> , 2019 , 17, 1556-1570	6.6	11
155	Genetic Ancestry-dependent Differences in Breast Cancer-induced Field Defects in the Tumor-adjacent Normal Breast. <i>Clinical Cancer Research</i> , 2019 , 25, 2848-2859	12.9	11
154	Flower isoforms promote competitive growth in cancer. <i>Nature</i> , 2019 , 572, 260-264	50.4	53
153	Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. <i>Nature Communications</i> , 2019 , 10, 2860	17.4	14
152	Interferon- β signaling is associated with loss-of-function mutations in high grade serous ovarian cancer. <i>Npj Precision Oncology</i> , 2019 , 3, 32	9.8	13
151	Attraction and Compaction of Migratory Breast Cancer Cells by Bone Matrix Proteins through Tumor-Osteocyte Interactions. <i>Scientific Reports</i> , 2018 , 8, 5420	4.9	18
150	An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. <i>Clinical Cancer Research</i> , 2018 , 24, 3163-3175	12.9	61
149	Mutational landscape of RNA-binding proteins in human cancers. <i>RNA Biology</i> , 2018 , 15, 115-129	4.8	47
148	A system for detecting high impact-low frequency mutations in primary tumors and metastases. <i>Oncogene</i> , 2018 , 37, 185-196	9.2	17

147	Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade. <i>Cancer Research</i> , 2018 , 78, 5107-5123	10.1	25
146	Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling. <i>International Journal of Oncology</i> , 2018 , 53, 1001-1012	4.4	9
145	Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis. <i>Breast Cancer Research</i> , 2018 , 20, 35	8.3	8
144	MMB triazole analogs are potent NF- κ B inhibitors and anti-cancer agents against both hematological and solid tumor cells. <i>European Journal of Medicinal Chemistry</i> , 2018 , 157, 562-581	6.8	18
143	Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model. <i>Oncotarget</i> , 2018 , 9, 9364-9378	3.3	8
142	Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells. <i>Cancer Research</i> , 2018 , 78, 3865-3876	10.1	31
141	Microfluidic channel for characterizing normal and breast cancer cells. <i>Journal of Micromechanics and Microengineering</i> , 2017 , 27, 035017	2	19
140	Individualized Breast Cancer Characterization through Single-Cell Analysis of Tumor and Adjacent Normal Cells. <i>Cancer Research</i> , 2017 , 77, 2759-2769	10.1	12
139	RareVar: A Framework for Detecting Low-Frequency Single-Nucleotide Variants. <i>Journal of Computational Biology</i> , 2017 , 24, 637-646	1.7	3
138	Inhibitory Effects of Dopamine Receptor D Agonist on Mammary Tumor and Bone Metastasis. <i>Scientific Reports</i> , 2017 , 7, 45686	4.9	27
137	Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2747-2758	6.1	14
136	Inflammation-associated microRNA changes in circulating exosomes of heart failure patients. <i>BMC Research Notes</i> , 2017 , 10, 751	2.3	29
135	Reduction in Migratory Phenotype in a Metastasized Breast Cancer Cell Line via Downregulation of S100A4 and GRM3. <i>Scientific Reports</i> , 2017 , 7, 3459	4.9	17
134	A Spectrum Graph-Based Protein Sequence Filtering Algorithm for Proteoform Identification by Top-Down Mass Spectrometry 2017 , 2017, 222-229	0.8	2
133	Statistical modeling for sensitive detection of low-frequency single nucleotide variants. <i>BMC Genomics</i> , 2016 , 17 Suppl 7, 514	4.5	2
132	Distinct Effects of Adipose-Derived Stem Cells and Adipocytes on Normal and Cancer Cell Hierarchy. <i>Molecular Cancer Research</i> , 2016 , 14, 660-71	6.6	8
131	Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. <i>Cancer Research</i> , 2016 , 76, 3989-4001	10.1	17
130	NF- κ B-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. <i>Cell Death and Disease</i> , 2015 , 6, e1608	9.8	35

129	TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 519-31	4.4	24
128	HOXB7 Is an ER α Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. <i>Cancer Discovery</i> , 2015 , 5, 944-59	24.4	56
127	Essential Components of Cancer Education. <i>Cancer Research</i> , 2015 , 75, 5202-5	10.1	5
126	Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization. <i>Scientific Reports</i> , 2015 , 5, 13526	4.9	31
125	Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells. <i>Oncotarget</i> , 2015 , 6, 12682-96	3.3	40
124	Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. <i>Journal of Pathology</i> , 2014 , 232, 369-81	9.4	80
123	Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle. <i>Cancer Research</i> , 2014 , 74, 4270-81	10.1	35
122	PROGeneV2: enhancements on the existing database. <i>BMC Cancer</i> , 2014 , 14, 970	4.8	256
121	The mushroom <i>Ganoderma lucidum</i> suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes. <i>International Journal of Oncology</i> , 2014 , 44, 2009-15	4.4	37
120	MicroRNA and Cancer Drug Resistance 2014 , 305-326		
119	Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing. <i>BMC Medical Genomics</i> , 2013 , 6, 21	3.7	19
118	Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. <i>Scientific Reports</i> , 2013 , 3, 2530	4.9	49
117	PROGene: gene expression based survival analysis web application for multiple cancers. <i>Journal of Clinical Bioinformatics</i> , 2013 , 3, 22		114
116	Role of AKT isoforms in breast cancer. <i>Journal of Pathology</i> , 2013 , 229, e1	9.4	6
115	ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. <i>Cancer Research</i> , 2013 , 73, 5821-33	10.1	81
114	HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ER α and inducing IL-6 expression. <i>Cancer Research</i> , 2013 , 73, 5449-58	10.1	73
113	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of breast cancer management. <i>Breast Cancer Management</i> , 2013 , 2, 189-191	0.7	
112	Journal Watch: Our expert highlights the most important research articles across the spectrum of topics relevant to the field of breast cancer management. <i>Breast Cancer Management</i> , 2013 , 2, 97-99	0.7	

111	FOXA1 is an independent prognostic marker for ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 881-90	4.4	92
110	Breast-cancer stem cells-beyond semantics. <i>Lancet Oncology, The</i> , 2012 , 13, e43-8	21.7	117
109	Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. <i>Cancer Nanotechnology</i> , 2012 , 3, 47-54	7.9	114
108	PROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data. <i>Journal of Clinical Bioinformatics</i> , 2012 , 2, 23		49
107	Journal Watch: Our expert highlights the most important research articles across a spectrum of topics relevant to the field of breast cancer management.. <i>Breast Cancer Management</i> , 2012 , 1, 117-118 ^{0.7}		
106	Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 7193-205	8.3	22
105	Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. <i>Breast Cancer Research</i> , 2011 , 13, R86	8.3	71
104	FOXA1 (forkhead box A1). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011 ,	2.3	1
103	High-level expression of forkhead-box protein A1 in metastatic prostate cancer. <i>Histopathology</i> , 2011 , 58, 766-72	7.3	46
102	Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. <i>Oncogene</i> , 2011 , 30, 1290-301	9.2	95
101	Biomarkers for breast cancer stem cells: the challenges ahead. <i>Biomarkers in Medicine</i> , 2011 , 5, 661-71	2.3	17
100	A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples. <i>Journal of Translational Medicine</i> , 2011 , 9, 80	8.5	11
99	A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF- κ B and generating reactive oxygen species. <i>International Journal of Cancer</i> , 2011 , 128, 2481-94	7.5	65
98	Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet. <i>Cancer Research</i> , 2010 , 70, 685-96	10.1	22
97	ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2010 , 10, 600-14	4.6	12
96	Loss of ER α and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. <i>Oncology Reports</i> , 2010 , 24, 1233-9	3.5	19
95	Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. <i>Modern Pathology</i> , 2010 , 23, 270-5	9.8	41
94	Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. <i>American Journal of Pathology</i> , 2010 , 176, 2139-49	5.8	36

93	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 97-108	4.4	148
92	SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. <i>BMC Cancer</i> , 2010 , 10, 411	4.8	132
91	A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. <i>Prostate</i> , 2010 , 70, 1074-86	4.2	56
90	Breast cancer stem cells and intrinsic subtypes: controversies rage on. <i>Current Stem Cell Research and Therapy</i> , 2009 , 4, 50-60	3.6	96
89	Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. <i>Journal of Clinical Pathology</i> , 2009 , 62, 6-12	3.9	67
88	Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. <i>Cancer Research</i> , 2009 , 69, 9192-201	10.1	101
87	Obesity potentiates the growth and dissemination of pancreatic cancer. <i>Surgery</i> , 2009 , 146, 258-63	3.6	101
86	Intrinsic subtype-associated changes in the plasma proteome in breast cancer. <i>Proteomics - Clinical Applications</i> , 2009 , 3, 1305-13	3.1	12
85	NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. <i>Cancer Letters</i> , 2009 , 278, 145-155	9.9	60
84	Estradiol-regulated microRNAs control estradiol response in breast cancer cells. <i>Nucleic Acids Research</i> , 2009 , 37, 4850-61	20.1	270
83	FOXA1 in breast cancer. <i>Expert Reviews in Molecular Medicine</i> , 2009 , 11, e8	6.7	48
82	Amplified in breast cancer 1 expression in breast cancer. <i>Histopathology</i> , 2008 , 53, 634-41	7.3	9
81	Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. <i>Carcinogenesis</i> , 2008 , 29, 25-34	4.6	63
80	AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. <i>Molecular and Cellular Biology</i> , 2008 , 28, 7487-503	4.8	82
79	Striatin-3 gamma inhibits estrogen receptor activity by recruiting a protein phosphatase. <i>Journal of Molecular Endocrinology</i> , 2008 , 40, 199-210	4.5	11
78	Antimyeloma effects of a sesquiterpene lactone parthenolide. <i>Clinical Cancer Research</i> , 2008 , 14, 1814-222.9		33
77	Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. <i>Carcinogenesis</i> , 2008 , 29, 1893-900	4.6	80
76	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. <i>Journal of Clinical Pathology</i> , 2008 , 61, 327-32	3.9	87

75	Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair. <i>Radiation Research</i> , 2007 , 168, 689-97	3.1	30
74	NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. <i>Oncogene</i> , 2007 , 26, 711-24	9.2	477
73	Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. <i>Oncogene</i> , 2007 , 26, 3329-37	9.2	94
72	MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters. <i>Experimental Hematology</i> , 2007 , 35, 1782-92	3.1	22
71	The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. <i>Journal of Biological Chemistry</i> , 2007 , 282, 445-53	5.4	53
70	Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1736-44	6.1	35
69	Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. <i>Cancer Research</i> , 2007 , 67, 7194-202	10.1	92
68	FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. <i>Clinical Cancer Research</i> , 2007 , 13, 4415-21	12.9	187
67	2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells. <i>Cancer Research</i> , 2007 , 67, 702-8	10.1	23
66	Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer. <i>Journal of Surgical Research</i> , 2007 , 143, 169-76	2.5	6
65	FOXA1 as a therapeutic target for breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 507-146.4		52
64	Identity profiling of cell surface markers by multiplex gold nanorod probes. <i>Nano Letters</i> , 2007 , 7, 2300-61.5	6.1	134
63	Negative regulation of MHC class II gene expression by CXCR4. <i>Experimental Hematology</i> , 2006 , 34, 1085-92	3.92	17
62	Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 1883-96	12.9	85
61	CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. <i>Breast Cancer Research</i> , 2006 , 8, R59	8.3	716
60	Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. <i>Prostate</i> , 2006 , 66, 1498-511	4.2	42
59	The Sesquiterpene Lactone Parthenolide Induces Apoptosis and Overcomes the Protective Effect of the Bone Marrow Microenvironment in Human Multiple Myeloma Cells.. <i>Blood</i> , 2006 , 108, 5058-5058	2.2	1
58	The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1004-12	6.1	135

57	TNFalpha resistance in MCF-7 breast cancer cells is associated with altered subcellular localization of p21CIP1 and p27KIP1. <i>Cell Death and Differentiation</i> , 2005 , 12, 98-100	12.7	11
56	The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. <i>Carcinogenesis</i> , 2005 , 26, 1706-15	4.6	57
55	The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. <i>Carcinogenesis</i> , 2005 , 26, 900-7	4.6	40
54	Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 587-94	6.1	99
53	Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. <i>Molecular Endocrinology</i> , 2004 , 18, 2603-15		72
52	Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. <i>Clinical Cancer Research</i> , 2004 , 10, 5501-7	12.9	142
51	Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. <i>Oncogene</i> , 2004 , 23, 7330-44	9.2	129
50	Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. <i>British Journal of Cancer</i> , 2004 , 90, 853-9	8.7	25
49	Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. <i>Investigational New Drugs</i> , 2004 , 22, 299-305	4.3	85
48	Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. <i>American Journal of Pathology</i> , 2003 , 163, 2531-41	5.8	67
47	NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. <i>Journal of Biological Chemistry</i> , 2003 , 278, 21631-8	5.4	497
46	Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. <i>Oncogene</i> , 2002 , 21, 2066-78	9.2	107
45	NF-kappaB and breast cancer. <i>Current Problems in Cancer</i> , 2002 , 26, 282-309	2.3	57
44	Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein. <i>Blood</i> , 2001 , 97, 2168-70	2.2	25
43	Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor kappaB-mediated antiapoptosis involving c-IAP2. <i>Blood</i> , 2001 , 98, 2508-17	2.2	34
42	Repression of GADD153/CHOP by NF-kappaB: a possible cellular defense against endoplasmic reticulum stress-induced cell death. <i>Oncogene</i> , 2001 , 20, 2178-85	9.2	100
41	Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. <i>Journal of Immunology</i> , 2001 , 167, 4137-40	5.2	284
40	The platelet-activating factor receptor protects epidermal cells from tumor necrosis factor (TNF) alpha and TNF-related apoptosis-inducing ligand-induced apoptosis through an NF-kappa B-dependent process. <i>Journal of Biological Chemistry</i> , 2001 , 276, 45548-54	5.4	36

39	Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. <i>Journal of Biological Chemistry</i> , 2001 , 276, 9817-24	5.4	707
38	Repression of transforming-growth-factor- β -mediated transcription by nuclear factor κ B. <i>Biochemical Journal</i> , 2000 , 348, 591	3.8	37
37	Repression of transforming-growth-factor- β -mediated transcription by nuclear factor κ B. <i>Biochemical Journal</i> , 2000 , 348, 591-596	3.8	108
36	Paclitaxel sensitivity of breast cancer cells with constitutively active NF- κ B is enhanced by κ B α super-repressor and parthenolide. <i>Oncogene</i> , 2000 , 19, 4159-69	9.2	253
35	The orphan receptor COUP-TFII regulates G2/M progression of breast cancer cells by modulating the expression/activity of p21(WAF1/CIP1), cyclin D1, and cdk2. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 270, 1144-53	3.4	33
34	Cancer cell-derived interleukin 1 α contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 275, 60-2	3.4	61
33	Negative regulation of transactivation function but not DNA binding of NF- κ B and AP-1 by κ B β 1 in breast cancer cells. <i>Journal of Biological Chemistry</i> , 1999 , 274, 18827-35	5.4	52
32	Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 255, 703-6	3.4	154
31	Binding and activation of the human aldehyde dehydrogenase 2 promoter by hepatocyte nuclear factor 4. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998 , 1399, 181-6		30
30	Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements. <i>Nucleic Acids Research</i> , 1998 , 26, 2491-9	20.1	87
29	Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase. <i>Blood</i> , 1998 , 92, 2450-2460	2.2	43
28	Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase. <i>Blood</i> , 1998 , 92, 2450-2460	2.2	6
27	NF- κ B activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1 α . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 6971-6	11.5	69
26	Constitutive activation of NF- κ B during progression of breast cancer to hormone-independent growth. <i>Molecular and Cellular Biology</i> , 1997 , 17, 3629-39	4.8	719
25	Differential effect of Nonidet P40 on DNA binding of transcription factors. <i>Analytical Biochemistry</i> , 1997 , 249, 103-4	3.1	9
24	Subunit association and DNA binding activity of the heterotrimeric transcription factor NF- κ B is regulated by cellular redox. <i>Journal of Biological Chemistry</i> , 1996 , 271, 28784-91	5.4	79
23	Isolation of retinoic acid-repressed genes from P19 embryonal carcinoma cells. <i>Gene</i> , 1996 , 174, 79-84	3.8	28
22	CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 3967-71	11.5	96

21	Differential whole-cell extract preparation and electrophoretic mobility shift assay to evaluate the effect of tyrosine phosphatases on DNA binding activity of transcription factors. <i>Analytical Biochemistry</i> , 1996 , 236, 178-81	3.1	2
20	Interaction of Oct-1 with TFIIB. Implications for a novel response elicited through the proximal octamer site of the lipoprotein lipase promoter. <i>Journal of Biological Chemistry</i> , 1995 , 270, 19613-23	5.4	50
19	Stage and tissue-specific expression of the alcohol dehydrogenase 1 (Adh-1) gene during mouse development. <i>Developmental Dynamics</i> , 1994 , 199, 199-213	2.9	42
18	The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinol-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4, and ARP-1 homo- and heterodimers. <i>Journal of Biological Chemistry</i> , 1994 , 269, 890-902	5.4	113
17	The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinol-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4, and ARP-1 homo- and heterodimers.. <i>Journal of Biological Chemistry</i> , 1994 , 269, 890-902	5.4	110
16	Retinoic acid signal transduction pathways. <i>Annals of the New York Academy of Sciences</i> , 1993 , 684, 19-34.5	4.2	42
15	RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo.. <i>EMBO Journal</i> , 1993 , 12, 2349-2360	13	223
14	RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. <i>EMBO Journal</i> , 1993 , 12, 2349-60	13	72
13	Retinoid receptors and binding proteins. <i>Journal of Cell Science</i> , 1992 , 16, 69-76	5.3	30
12	Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. <i>Cell</i> , 1992 , 70, 1007-19	56.2	339
11	Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. <i>Cell</i> , 1992 , 68, 377-95	56.2	1130
10	The first 124 nucleotides of the E7 coding sequences of HPV16 can render the HPV11 genome transformation competent. <i>Virology</i> , 1992 , 186, 348-51	3.6	11
9	Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 10138-42	11.5	187
8	Activity and enhancer binding factors for BK virus regulatory elements in differentiating embryonal carcinoma cells. <i>Virology</i> , 1991 , 183, 374-80	3.6	7
7	A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter.. <i>EMBO Journal</i> , 1991 , 10, 2223-2230	13	161
6	A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter. <i>EMBO Journal</i> , 1991 , 10, 2223-30	13	59
5	Ubiquitous and cell-type-specific protein interactions with human papillomavirus type 16 and type 18 enhancers. <i>Virology</i> , 1990 , 178, 92-103	3.6	25
4	Activity and enhancer binding factors for JC virus regulatory elements in differentiating embryonal carcinoma cells. <i>Virology</i> , 1990 , 177, 784-9	3.6	14

- 3 Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. *Nature*, **1988**, 335, 832-5 50.4 132
- 2 Functional role of BK virus tumor antigens in transformation. *Journal of Virology*, **1988**, 62, 4613-21 6.6 18
- 1 Aged Breast Extracellular Matrix Drives Mammary Epithelial Cells to an Invasive and Cancer-Like Phenotype 2